Caribou Biosciences, Inc.

Stage 4 · Declining · week 16

As of Oct 22, 2026, Caribou Biosciences is in Stage 4, the downtrend phase, now in week 16 (since Jul 7, 2026). It closed at $0.56, 77.9% below its 52-week high and below its 200-day average, which is falling.

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. More about the company

$0.56

+1.84% today

$60.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CRBU early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S4 23w

S2 19w

S4 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 2w → S2 4w → S3 3w → S4 8w → S1 4w → S2 13w → S3 3w → S4 19w → S1 4w → S4 5w → S1 8w → S4 23w → S1 7w → S2 19w → S3 7w → S4 6w → S1 6w → S2 8w → S3 2w → S4 15w current

Total tracked: 165 weeks across 20 stage runs.

CRBU among Biotechnology467th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…467	CRBUCaribou Biosciences, Inc.	Stage 4 · wk 16	11	−56.6%

vs 52W High

-77.9%

$0.46 lo$2.53 hi

77.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 16

1w13w26w

Week 16, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-66.4%

200 DMA: $1.67 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.98x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-56.6%

-64.3%

-75.2%

YTD

-64.8%

-80.3%

Scan Membership

Breakout Watch

Latest: 2024-01-08

3 appearances in last 60 days. First seen: 2022-09-26.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 16 · Vol 0.98x

2026-10-21S4

Wk 16 · Vol 0.73x

2026-10-20S4

Wk 15 · Vol 1.23x

2026-10-19S4

Wk 15 · Vol 1.40x

2026-10-16S4

Wk 15 · Vol 1.10x

2026-10-15S4

Wk 15 · Vol 1.09x

2026-10-14S4

Wk 15 · Vol 1.43x

2026-10-13S4

Wk 14 · Vol 1.79x

2026-10-12S4

Wk 14 · Vol 2.15x

2026-10-09S4

Wk 14 · Vol 4.28x

2026-10-08S4

Wk 14 · Vol 10.10x

2026-10-07S4

Wk 14 · Vol 31.15x

Moving averages & range

50 DMA

$1.21

200 DMA

$1.67

52W High

$2.53

52W Low

$0.46

5D Low

$0.46

Resistance levels (recent highs)

20d High

$1.27

60d High

$1.76

120d High

$2.43

250d High

$2.49

Next resistance

+126.8%

to 20d High

ROE

-78.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.6

Caribou Biosciences: quick answers

What stage is Caribou Biosciences in?

As of Oct 22, 2026, Caribou Biosciences (CRBU) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 7, 2026 and is in week 16. What the four stages mean

Is Caribou Biosciences in an uptrend?

No. Caribou Biosciences is in a Stage 4 downtrend. It trades 66.4% below its 200-day average, which is falling.

How far is Caribou Biosciences from its 52-week high?

Caribou Biosciences closed at $0.56 on Oct 22, 2026, 77.9% below its 52-week high of $2.53. Its 52-week low is $0.46.

How has Caribou Biosciences performed over the past year?

As of Oct 22, 2026, Caribou Biosciences is down 80.3% over the past year and down 64.8% so far in 2026.

Which sector and industry is Caribou Biosciences in?

Caribou Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.